Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endomorphin-2
- Development stage
- Unknown
- Lead developer
- Cytogel Pharma
- Modality
- Peptides
- Administration
- Intracerebroventricular (i.c.v.)
01
Overview
Endomorphin-2 is an endogenous opioid peptide, acting as a high-affinity and highly selective agonist of the μ-opioid receptor. It is involved in analgesia and is more prevalent in the spinal cord than in the brain. Its sequence is Tyr-Pro-Phe-Phe-NH2. It is known for its antinociceptive activity and has been studied for its potential roles in pain management.
- Other names
- Endomorphin-2Endomorphin2Endomorphin 2EM2EM-2EM 2
02
Targets
KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on endomorphin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endomorphin-2.